Taro Provides Results for September 30, 2016
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
Taro Pharma (TARO) Reports Q2 EPS of $3.00
November 8, 2016 5:33 PM ESTTaro Pharma (NYSE: TARO) reported Q2 EPS of $3.00, versus $3.11 reported last year. Revenue for the quarter came in at $228.8 million, versus $212.06 million reported last year.
For earnings history and earnings-related data on Taro Pharma (TARO) click here.
... More